Genmab to vigorously defend trade secret misappropriation claims by AbbVie Inc.

Genmab, a biotechnology company based in Denmark, recently revealed their plans to work on advancing cancer research and treatment through collaboration with Adaptive Biotechnologies. The partnership between the two companies aims to leverage Genmab’s expertise in antibody technology and Adaptive Biotechnologies’ proficiency in T-cell receptors to develop new therapies for cancer patients.

Genmab is renowned for its innovative approach to creating antibody-based therapies, which have shown promise in treating various types of cancer. By joining forces with Adaptive Biotechnologies, a leader in T-cell receptor sequencing and analysis, Genmab hopes to enhance their capabilities in developing personalized cancer treatments that harness the body’s immune system to target specific cancer cells.

The collaboration will focus on identifying and validating targets for new antibody-based cancer therapies by combining Genmab’s proprietary antibody platforms with Adaptive Biotechnologies’ expertise in identifying T-cell targets. By analyzing the immune system’s response to cancer cells, the two companies aim to uncover new therapeutic targets that can be used to develop novel cancer treatments with improved efficacy and safety profiles.

According to Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab, the collaboration with Adaptive Biotechnologies aligns with Genmab’s commitment to advancing cancer research and developing innovative treatments for patients in need. He expressed enthusiasm for the partnership, highlighting the potential of combining Genmab’s antibody technology with Adaptive Biotechnologies’ T-cell receptor expertise to create groundbreaking therapies that could improve outcomes for cancer patients.

Chad Robins, Chief Executive Officer, and Co-Founder of Adaptive Biotechnologies also shared his optimism about the collaboration, emphasizing the complementary nature of the two companies’ capabilities. By combining their respective strengths in antibody technology and T-cell receptor analysis, Robins believes that Genmab and Adaptive Biotechnologies can accelerate the development of new cancer therapies that may have a significant impact on patient care.

The partnership between Genmab and Adaptive Biotechnologies represents a significant step forward in the field of cancer research and treatment. By leveraging their combined expertise and resources, the two companies are well-positioned to make meaningful contributions to the development of novel therapies that could benefit cancer patients worldwide. As they embark on this collaborative journey, Genmab and Adaptive Biotechnologies are poised to drive innovation in cancer treatment and bring new hope to those affected by this devastating disease.